Project Details
Description
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of SU011248 in the Treatment of Patients with Imatinib Mesylate (Gleevec, Glivec)-Resistant or Intolerant
| Status | Finished |
|---|---|
| Effective start/end date | 9/19/03 → 8/31/10 |
Funding
- SUGEN INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.